

#### Measuring an epidemic: using EHR data to track trends in opioid prescribing

John Muench, MD, MPH Thuy Le, MPH Jon Puro, MPA:HA

# You Draw It: Just How Bad Is the Drug Overdose Epidemic?

By JOSH KATZ APRIL 14, 2017



*An influential report of a small case series of atypical chronic pain patients using opioids long-term* 

Pain, 25 (1986) 171–186 Elsevier

### Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases

Russell K. Portenoy and Kathleen M. Foley

Pain Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center, and Department of Neurology, Cornell University Medical College, New York, NY 10021 (U.S.A.)

(Received 10 June 1985, accepted 28 October 1985)

American Pain Society (APS) & American Academy of Pain Medicine (AAPM), 1996 Guidelines

**Addiction:** "Misunderstanding of addiction and mislabeling of patients as addicts result in unnecessary withholding of opioid medications."

**Tolerance:** "For most opioids, there does not appear to be an arbitrary upper dosage limit."

**Diversion:** "Efforts to stop diversion should not interfere with prescribing opioids for pain management."

**Overdose:** "Respiratory depression induced by opioids tends to be a short-lived phenomenon, generally occurs only in the opioid-naive patient, and is antagonized by pain."

# Pharma promotion

- "There's no question that our best, strongest pain medicines are the opioids, but these are the same drugs that have a reputation for causing addiction and other terrible things."
- "They don't wear out. They go on working."
- "They do not have serious medical side effects...these drugs should be used much more than they are for patients in pain..."

Promotional video, Purdue Pharma, 1999

## National, state, local policies

- The Oregon Intractable Pain Act, passed in 1995, allowed physicians to prescribe controlled substances for treatment of chronic pain without sanction from the Oregon Medical Board.
  - The Oregon Pain Commission advocated for appropriate patient access to pain management...
    - McCarty, D., R. Bovett, T. Burns, J. Cushing, M. E. Glynn, S. J. Kruse, L. M. Millet, and J. Shames. "Oregon's Strategy to Confront Prescription Opioid Misuse: A Case Study." J Subst Abuse Treat 48, no. 1 (Jan 2015): 91-5.
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO) – 2001. All patients assessed for pain (5<sup>th</sup> vital sign)

Opioid Prescriptions Dispensed by US Retail Pharmacies IMS Health, Vector One



Nora Volkow report to congress May 14, 2014 (NIDA website)

### Hints of problems: NY Times July 29, 2001

Magazine

### The Alchemy of OxyContin

By PAUL TOUGH JULY 29, 2001

Paula is taking me on a driving tour of Man, the tiny West Virginia town where she has spent her entire life. Because I don't know my way around the hollows and gullies and creeks that carve through these hills, Paula is at the wheel. And because Paula isn't a morning person, we've set out on our tour at midnight. It's dark; the only illumination comes from our headlights cutting through the mist that rolls down from the hills.

The tour Paula is leading isn't sanctioned by the local chamber of

### USA Today 2/13/2007

V

<b>EUSA</b> TODAY.	Home	News	Travel	Money	Sports	Life	Tech	Weat

Deadly abuse of methadone tops other prescription drugs

Updated 2/13/2007 9:04 AM ET

Inside News

Nation

E-mail | Print |

Cars = E\



#### By Donna Leinwand, USA TODAY

Methadone, a painkiller that has been used to treat heroin addicts for decades, has emerged as an increasingly popular and deadly street drug, joining narcotics such as Vicodin and OxyContin as frequently abused prescription drugs.

Fatal overdoses of methadone rose at a higher rate than those involving any other narcotic from 1999 through 2004, according to a recent study by the National Center for Health Statistics (NCHS). The number of deaths from methadone in 2004 (3,849) represented a 390% rise from 1999, the study said.

#### ON THE STREET: Painkiller becomes more available

Methadone was cited in nearly 13% of all the overdose deaths reported in the USA in 2004, up from about 4% five years earlier. Among drugs cited in fatal overdoses, only cocaine kills more people than methadone.

Enlarge

By Chuck Branham, The Evening News via AP

### The Oregonian, April 12, 2010 Heroin isn't the drug that's killing most Oregonians

- More people in the 35- to 54-year-old age group die of unintentional overdoses than from motor vehicle accidents. Methadone is a particularly bad actor...
- More individuals die from overdoses of prescription medications than heroin, cocaine and methamphetamine combined...



Your Source for Credible Health Information

#### Overdose Deaths Involving Opioids, United States, 2000-2015

SOURCE: CDC/NCHS, National Vital Statistics System, Mortality. CDC WONDER, Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://wonder.cdc.gov/.



### For every action...?

- Beginning 2000 Anecdotes in the popular press.
- 2007 Purdue pharmaceutical settlement
- 2010 Oxycontin reformulated to prevent injection use
- Prescription drug monitoring programs (PDMPs) 25 in 2005. 46 in 2011
- 2011 ONDCP report Epidemic: Responding to America's Prescription Drug Abuse Crisis
- 2011 Portland, OR local FQHC policies
- 2012 National Governors Association State Policy Academy on Reducing Prescription Drug Abuse.
- 2014 opioid/acetaminophen combinations rescheduled from category 3 to 2
- 2016 CDC safe prescribing guideline published
- 2016 Surgeon general communication to all prescribers



(b) Motion of a simple pendulum



# Oregon House passes bill seeking to stem opioid epidemic

#### **BY ANDREW SELSKY**

The Associated Press

6:50 P.M., APRIL 10, 2017



SALEM — Seeking to stem the opioid epidemic in Oregon and prevent overdose deaths, the state House of Representatives unanimously approved a proposed law on Monday that would provide safe-use recommendations to those who prescribe such pain-killing drugs.

However, provisions in the bill that would have limited health-care practitioners to prescribing a maximum seven-day supply













- "In the United States guideline [2009], 21 of 25 recommendations were viewed as supported by only lowquality evidence."
- "In other words, the developers of the guidelines found that what we know about opioids is dwarfed by what we don't know."
  - Chou, R. "What We Still Don't Know About Treating Chronic Noncancer Pain with Opioids." *CMAJ* 182, no. 9 (Jun 15 2010): 881-2.

## What do we want to know?

- What policies led to over-prescribing of opioids?
- What policies will lead to more appropriate prescribing?
- What pain conditions most commonly lead to opioid use?
- What other patient characteristics are associated with opioid use for pain? With overdose?
- Are some opioids better than others? Are some delivery methods better? LA vs SA? Benefits/Harms?
- What are the best ways to monitor patient opioid use risk?
- How can we identify overdoses in ambulatory records? In ED records?
- How can we better treat pain if not with opioids?
- How can we better treat substance use disorders and overdose to which overprescribing has contributed?



#### +

Chou, R. "What We Still Don't Know About Treating Chronic Noncancer Pain with Opioids." *CMAJ* 182, no. 9 (Jun 15 2010): 881-2.

- The principles of research into comparative effectiveness are well suited for addressing these and other research gaps. Rather than evaluating whether yet another opioid is more effective than nothing in low-risk patients, such research focuses on the benefits and harms of interventions in populations similar to those encountered in clinical practice, emphasizing the need to understand the trade-offs between different interventions (e.g., different opioids).
- These principles can be applied to the evaluation of different strategies for risk assessment, patient selection, dosing, management and monitoring, using a broad range of study designs, including observational studies of large databases or registries

# + How have we studied opioids in populations up to now?

NSDUH - National Survey on Drug Use and Health

- Paulozzi, L., C. M. Jones, K. Mack, and R. A. Rudd. "Vital Signs: Overdoses of Prescription Opioid Pain Relievers - United States, 1999-2008." MMWR Morb Mortal Wkly Rep 60, no. 43 (2011): 1487-92.
- NHANES National Health and Nutrition Examination Survey
  - Frenk, S.M., K.S. Porter, and L. Paulozzi. "Prescription Opioid Analgesic Use among Adults: United States, 1999-2012." In NCHS data brief, edited by National Center for Health Statistics. Hyattsville, MD, 2015.
- NAMCS National Ambulatory Medical Care Survey
  - Olsen, Y., G. L. Daumit, and D. E. Ford. "Opioid Prescriptions by U.S. Primary Care Physicians from 1992 to 2001." J Pain 7, no. 4 (Apr 2006): 225-35.
  - Daubresse, M., H.Y. Chang, Y.Yu, S. Viswanathan, N. D. Shah, R. S. Stafford, S. P. Kruszewski, and G. C. Alexander. "Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000-2010." *Med Care* 51, no. 10 (Oct 2013): 870-8.
  - Olfson, M., S. Wang, M. Iza, S. Crystal, and C. Blanco. "National Trends in the Office-Based Prescription of Schedule Ii Opioids." *J Clin Psychiatry* 74, no. 9 (Sep 2013): 932-9.
  - Prunuske, J. P., C. A. St Hill, K. D. Hager, A. M. Lemieux, M. T. Swanoski, G. W. Anderson, and M. N. Lutfiyya. "Opioid Prescribing Patterns for Non-Malignant Chronic Pain for Rural Versus Non-Rural Us Adults: A Population-Based Study Using 2010 Namcs Data." *BMC Health Serv Res* 14 (Nov 19 2014): 563.

#### + Pharmacy Claims Databases

- Sullivan, M. D., M. J. Edlund, M. Y. Fan, A. Devries, J. Brennan Braden, and B. C. Martin. "Trends in Use of Opioids for Non-Cancer Pain Conditions 2000-2005 in Commercial and Medicaid Insurance Plans: The Troup Study." *Pain* 138, no. 2 (Aug 31 2008): 440-9.
- Morden, N. E., J. C. Munson, C. H. Colla, J. S. Skinner, J. P. Bynum, W. Zhou, and E. Meara. "Prescription Opioid Use among Disabled Medicare Beneficiaries: Intensity, Trends, and Regional Variation." *Med Care* 52, no. 9 (Sep 2014): 852-9.– Medicare <65yo.</li>
- Edlund, M. J., M. A. Austen, M. D. Sullivan, B. C. Martin, J. S. Williams, J. C. Fortney, and T. J. Hudson. "Patterns of Opioid Use for Chronic Noncancer Pain in the Veterans Health Administration from 2009 to 2011." *Pain* 155, no. 11 (Nov 2014): 2337-43.
- Paulozzi, L. J., K. A. Mack, and J. M. Hockenberry. "Variation among States in Prescribing of Opioid Pain Relievers and Benzodiazepines--United States, 2012." J Safety Res 51 (Dec 2014): 125-9.
- Mack, K. A., K. Zhang, L. Paulozzi, and C. Jones. "Prescription Practices Involving Opioid Analgesics among Americans with Medicaid, 2010." J Health Care Poor Underserved 26, no. 1 (Feb 2015): 182-98.
- Kuo, Y. F., M. A. Raji, N. W. Chen, H. Hasan, and J. S. Goodwin. "Trends in Opioid Prescriptions among Part D Medicare Recipients from 2007 to 2012." *Am J Med* 129, no. 2 (Feb 2016): 221 e21-30. (Medicare >65yo)

- Johnson, H., L. Paulozzi, C. Porucznik, K. Mack, B. Herter. "Decline in Drug Overdose Deaths after State Policy Changes - Florida, 2010-2012." MMWR Morb Mortal Wkly Rep 63, no. 26 (Jul 04 2014)
  - In 2010 Florida was home to 98 of the 100 U.S. physicians who dispensed the highest quantities of oxycodone.
  - Several legislative measures enacted in 2010/2011
     –February 2011; statewide raids of problem clinics.
  - Opioid prescription rates for selected drugs calculated from IMS Health National Prescription Audit (NPA) decreased significantly 2010 to 2012, and especially oxycodone (24%)
  - Florida Medical Examiners Commission (FMEC) data from 200102012 showed opioid overdose deaths declined 27%, again, especially those attributable to oxycodone (52%)

### Prescription Drug Monitoring Programs (PDMPs)

- Paulozzi, L. J., G. K. Strickler, P. W. Kreiner, C. M. Koris, Control Centers for Disease, and Prevention. "Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013." MMWR Surveill Summ 64, no. 9 (Oct 16 2015): 1-14.
- Deyo, R. A., S. E. Hallvik, C. Hildebran, M. Marino, E. Dexter, J. M. Irvine, N. O'Kane, et al. "Association between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use among Opioid-Naive Patients: A Statewide Retrospective Cohort Study." J Gen Intern Med 32, no. 1 (Jan 2017): 21-27.

How can we better leverage clinical data warehouses to track opioid prescribing?

- Most major institutions began implementing EHRs after 2005

   if this tool had been available in 1990, could we have
   understood the problem better and addressed it earlier?
- Clinical data is a more granular look at details of encounters in which opioids have been prescribed.



#### Clinical data entry

# Data warehouse structure and organization

Extraction into population reports with meaning

Hulley, Stephen B., Steven R. Cummings, and Warren S. Browner. Designing Clinical Research : An Epidemiologic Approach. Baltimore: Williams & Wilkins, 1988



### + Studies using EHR data

#### The CONSORT study

- Von Korff, M., K. Saunders, G. Thomas Ray, D. Boudreau, C. Campbell, J. Merrill, M. D. Sullivan, et al. "De Facto Long-Term Opioid Therapy for Noncancer Pain." Clin J Pain 24, no. 6 (Jul-Aug 2008): 521-7.
- Boudreau, D., M. Von Korff, C. M. Rutter, K. Saunders, G. T. Ray, M. D. Sullivan, C. I. Campbell, et al. "Trends in Long-Term Opioid Therapy for Chronic Non-Cancer Pain." *Pharmacoepidemiol Drug Saf* 18, no. 12 (Dec 2009): 1166-75.
- Campbell, C. I., C. Weisner, L. Leresche, G. T. Ray, K. Saunders, M. D. Sullivan, C. J. Banta-Green, et al. "Age and Gender Trends in Long-Term Opioid Analgesic Use for Noncancer Pain." Am J Public Health 100, no. 12 (Dec 2010): 2541-7.
- Deyo, R. A., D. H. Smith, E. S. Johnson, M. Donovan, C. J. Tillotson, X. Yang, A. F. Petrik, and S. K. Dobscha. "Opioids for Back Pain Patients: Primary Care Prescribing Patterns and Use of Services." J Am Board Fam Med 24, no. 6 (Nov-Dec 2011): 717-27.
- Mosher, H. J., E. E. Krebs, M. Carrel, P. J. Kaboli, M. W. Weg, and B. C. Lund. "Trends in Prevalent and Incident Opioid Receipt: An Observational Study in Veterans Health Administration 2004-2012." J Gen Intern Med 30, no. 5 (May 2015): 597-604.

### Introducing the ADVANCE Clinical Data Research Network

Jon Puro, MPA:HA Principle Investigator, ADVANCE

#### The ADVANCE CDRN Partners

OCHIN, Inc. 97 health systems; 597 clinics; 17 states

Health Choice Network (HCN)

24 health systems; 465 clinics; 8 states

Legacy Health System

#### Care Oregon Medicaid Managed Care Plan

American Academy of Family Physicians, Robert Graham Center Fenway Health 3 clinics; 1 state

Kaiser Permanente NW Center for Health Research

Oregon Health and Sciences University (OHSU)

#### The ADVANCE CDRN



#### Patient Distribution by Clinic's State

## ADVANCE Research Data Warehouse (RDW) includes:

#### **PCORnet CDM**

Demographics (DOB, sex, race, etc.)

Enrollment

Encounter

Diagnosis

Labs

**Prescribing and Dispensing** 

Death date and cause

Vital Signs (height, weight, tob.)

Condition (incl. Problem List)

Patient Reported Outcomes

Plus additional data needed for research on the safety net:

- Federal Poverty Level (FPL)
- Household income and size
- Insurance status (incl. uninsured)
- Homeless status
- Migrant/seasonal worker status
- Veteran status
- Community Vital Signs

# + OVERVIEW:

- ADVANCE prescribing data
- Methods used in identifying opioid medications
  - Step I: Identify opioid classes using RxClass and RxNav
  - Step II: Identify additional opioid medications with missing RxNorms using text searches; obtain RxNorms using RxMix.
- Preliminary results

#### + Terminology

- **RxNorm**: Standardized terminology for identifying both generic and brand-name drugs.
- **RxCUI**: RxNorm concept unique identifier for a clinical drug.
- Raw\_Rx\_Med\_Name: An optional field in the prescribing CDM table.
- **RxClass**: Web based application to look at drug class hierarchies to find RxNorm.
- **RxNav**: Web based application to search for different drug characteristics across different classification systems.
- RxMix: Web based application that can be used to create programs to search for RxNorm functions. Allow users to run programs instantly or in batch mode.
- NDC: National Drug Code. It is a unique 10-digit, 3-segment number. It is a universal product identifier for human drugs in the US.

#### + Advance prescribing data

- All prescribed medications are included, even if some cannot be mapped to RxNorm.
  - >95% mapped to RxNormCUI.
- Medication reconciliation/active med list records are not included in the Prescribing table.
- Contain optional fields such as Raw\_Rx\_Med\_Name and Raw\_RxNorm\_CUI.
  - Raw\_Rx\_Med\_Name may contain both generic and brand named medications

#### + Step I: using RxClass and RxNav

- RxClass
  - Web based application created by NIH to look at drug class hierarchies to find RxNorm.
    - NDC code cannot be used in the search.
    - Shows links to clinical drugs (brand and generic), to their active ingredients, drug components, and related brand names.
  - Contain 9 drug class trees:
    - Anatomical Therapeutic Chemical (ATC1-4)
    - Established Pharmacologic Classes (EPC)
    - MeSH Pharmacologic Actions (MESHPA)
    - Disease
    - Chemical Structure (Chem)
    - Mechanism of Action (MoA)
    - Physiologic Effect (PE)
    - Pharmacokinetics (PK)
    - VA Classes (VA)



Q

🚔 Print

#### NIH U.S. National Library of Medicine

- > Names from Hum Ina
- > Names from Ina Int
- Names from Int Leu
- Names from Leu Loc
- > Names from Loc Muc
- > Names from Muc Non
- ✓ Names from Non Osm
  - Non-Standardized Insect Allergenic Extract (9)
  - Non-Standardized Insect Venom Allergenic Extract (2)
  - Non-Standardized Plant Allergenic Extract (76)
  - Non-Standardized Plant Fiber Allergenic Extract (5)
  - Non-Standardized Pollen Allergenic Extract (232)
  - Noncompetitive AMPA Glutamate Receptor Antagonist (1)
  - Nondepolarizing Neuromuscular Blocker (5)
  - Nonergot Dopamine Agonist (2)
  - Nonsteroidal Anti-inflammatory Drug (21)
     Norepinephrine Releasing Agent (1)
  - Norepinephrine Reuptake Inhibitor (1)
  - Norepinephrine Reuptake Inhibitor Anorectic (0)

Norepinephrine, Serotonin, and Dopamine Reuptake

#### Inhibitor Anorectic (0)

- Nucleoside Analog (0)
- Nucleoside Analog Antifungal (1)
- Nucleoside Analog Antiviral (4)
- Nucleoside Metabolic Inhibitor (12)
- Nucleotide Metabolic Inhibitor (0)
- Omega-3 Fatty Acid (1)
- Opioid Agonist (18)
- Opioid Agonist/Antagonist (2)
- Opioid Analgesic (0)
- Opioid Antagonist (6)
- Orexin Receptor Antagonist (1)
   Osmotic Diuretic (1)
- > Names from Osm Pho
- > Names from Pho Pro
- > Names from Pro Rad
- > Names from Rad Ser
- > Names from Ser Sul
- > Names from Sul Top
- > Names from Tri Vit
- > Names from Vit Xan
- > MeSH Pharmacologic Actions (MESHPA)
- Disease
- Chemical Structure (Chem) Ifrom DailuMod

RxClass: https://mor.nlm.nih.gov/RxClass/

#### RxClass

Exploring drug classes and their RxNorm drug members

Search...

O by class name/id O by RxNorm drug name/id I ingredient drug only T Edit Drug Sources

Opioid Agonist 🛓

class: Opioid Agonist / id: N0000175690 / class type: EPC / show context

#### 18 RxNorm generic drugs for has EPC in DailyMed / similar classes

Type 🔶	RXCUI ¢	RxNorm Name	Relation 🗢	All classes 🔶
IN	480	Alfentanii	DIRECT	Show
IN	2670	Codeine	DIRECT	Show
IN	23088	dihydrocodeine	DIRECT	Show
IN	4337	Fentanyl	DIRECT	Show
IN	5489	Hydrocodone	DIRECT	Show
IN	3423	Hydromorphone	DIRECT	Show
IN	6378	Levorphanol	DIRECT	Show
IN	6468	Loperamide	DIRECT	Show
IN	6754	Meperidine	DIRECT	Show





NIH U.S. National Library of Me	edicine				About Disclaimer	FAQ 1
Navigating RxNorm Drug	19	<ul> <li>String</li> </ul>			Q	
PyNorm Graph PyNorm Prope	ties NDC PyTerms NDE-PT Pill Images Class View	Interaction View				
Views IN/M	IN Ingredient (42)		PIN Precise Ingredient (5)	BN	Brand Name (70)	
Classic H RX Simple Co Table Co Filters Co H Human Co H RX V Vet Co	S HYDROcodone M Acetaminophen / Aspirin / Caffeine / HYDROcodone Acetaminophen / butaibital / Caffeine / HYDROcodone Acetaminophen / Caffeine / Chlorpheniramine / HYDROcodone Phenylephrine Acetaminophen / HYDROcodone Aspirin / Caffeine / HYDROcodone		HXE S HYDROcodone Bilartrate     S HYDROcodone HCL     Hx: S HYDROcodone POLISTIREX     S HYDROcodone RESIN COMPLEX     S HYDROcodone tannate		B-Tuss Baltussin HC Bromplex HD Cytuss-HC NR De-Chlor G De-Chlor HC De-Chlor MR	
Image: Section of the section of t	Clinical Drug Component (32) HYDROcodone Bitartrate 0.333 MG/ML HYDROcodone Bitartrate 0.334 MG/ML HYDROcodone Bitartrate 0.34 MG/ML HYDROcodone Bitartrate 0.34 MG/ML HYDROcodone Bitartrate 0.5 MG/ML HYDROcodone Bitartrate 0.65 MG/ML HYDROcodone Bitartrate 0.65 MG/ML	×		SBD: H RX M H RX M H RX M H RX M	Branded Drug Component (106) Acetaminophen 20 MG/ML / HYDROCodone Bitartrate 0.667 MG// [Lortab] Acetaminophen 21.7 MG/ML / HYDROCodone Bitartrate 0.5 MG// Acetaminophen 21.7 MG/ML / HYDROcodone Bitartrate 0.67 MG// Acetaminophen 21.7 MG/ML / HYDROcodone Bitartrate 0.67 MG// [Zamicet] Acetaminophen 300 MG / HYDROcodone Bitartrate 10 MG [Acetaminophen 300 MG / HYDROCodone Bitartrate 10 MG [Mcod	ML [Hycet] AL [Zyfrel] ML in]
MIN (2 Pack SCD/G	PCK	Clinical Drug	g or Pack (98)	SBD/BF	CK Branded Drug or Pack (106)	
Multi     If Rs       rownload     If Rs       If Rs     If Rs	11 1 HR CHLORPHENIRAMINE POLISTIREX 1.6 MG/ML / HYDR     12 HR CHLORPHENIRAMINE POLISTIREX 4 MG / HYDROcodi     12 HR CHLORPHENIRAMINE POLISTIREX 8 MG / HYDROcodi     12 HR HYDROcodone Bitartrate 10 MG Extended Release Oral     12 HR HYDROcodone Bitartrate 15 MG Extended Release Oral     12 HR HYDROcodone Bitartrate 10 MG Extended Release Oral     12 HR HYDROcodone Bitartrate 10 MG Extended Release Oral     12 HR HYDROcodone Bitartrate 10 MG Extended Release Oral     12 HR HYDROcodone Bitartrate 30 MG Extended Release Oral     12 HR HYDROcodone Bitartrate 30 MG Extended Release Oral	Ocodone POLISTIRE one POLISTIREX 5 M one POLISTIREX 10 Capsule Capsule Capsule Capsule Capsule	EX 2 MG/ML Extended Release Suspension IG Extended Release Oral Capsule MG Extended Release Oral Capsule	H RX S H RX S	12 HR Zohydro 10 MG Extended Release Oral Capsule 12 HR Zohydro 15 MG Extended Release Oral Capsule 12 HR Zohydro 20 MG Extended Release Oral Capsule 12 HR Zohydro 30 MG Extended Release Oral Capsule 12 HR Zohydro 40 MG Extended Release Oral Capsule 12 HR Zohydro 50 MG Extended Release Oral Capsule APAP 20 MG/ML / HYDROcodone Bitartrate 0.667 MG/ML Oral So	olution -
SCE	G Clinical Dose Form Group (47)		DFG Dose Form Group (3)	SBDC	Branded Dose Form Group (139)	
	M Acetaminophen / HYDROcodone Oral Liquid Product Acetaminophen / HYDROcodone Oral Product Acetaminophen / HYDROcodone Pill Aspirin / HYDROcodone Oral Product Aspirin / HYDROcodone Oral Product Brompheniramine / guaiFENesin / HYDROcodone Oral Liquid P Brompheniramine / guaiFENesin / HYDROcodone Oral Liquid P	roduct	wxxxS Oral Liquid Product wxxS Oral Product wxxS Pill		B-Tuss Oral Liquid Product B-Tuss Oral Product Baltussin HC Oral Liquid Product Baltussin HC Oral Product Bromplex HD Oral Product Bromplex HD Oral Product Cytuss-HC NR Oral Liquid Product	

RxNav: https://mor.nlm.nih.gov/RxNav/

# + Step I: using RxClass and RxNav



U.S. National Library	of Medicine									About Disc	leimer FAQ	*							
15	VAV		0 RXCUI ¥ 5489	<u> </u>						Q									
Navigating F	xNorm Drugs		HYDROcodone [RxCUI =	5489]	🖬 🖯 5	- c≥ - <del>-</del>												RxNav	/_5489_simple (2)
Ralion Graph RxNorm	roperties NDC RaTe	ma NDF-RT Pill Images Class View Interaction View			FILE H	OME INS	ERT P	PAGE LAYOL	JT FORM	VULAS	DATA R	REVIEW \	VIEW DEV	VELOPER	SAS				
Views	INMIN	Ingredient		BN	Cut	t	Calibri	~	11 - A	A* = =	- 🛷	- 🗟 Wr	ap Text	Gene	ral	~			Normal
• Clessic	SCOIGPER	Clinical Drug or Pack		волерск	Paste	py *	BI	<b>u</b>	- & - A	= =		🚛 🖽 Me	rae & Center	- 5	% *	58 .28	Conditional	Format as	Check Cell
· Error	V HOR	Ocodone (14)		B-Tuss (1)	🚽 🗸 💎 For	mat Painter									, 0	F	ormatting ~	Table -	
. 1000	H H 12 HR I	HYDROcodone Bitartrate 10 MG Extended Release Oral Capsule		B-Tusa (chlorphe	nram Clipboa	rd 🖙		Font		r <sub>M</sub>	A	lignment		r <sub>34</sub>	Number	F24			
Fillers	11 12 12 HR	HYDROcodone Blartrate 15 MG Extended Release Oral Capsule HYDROcodone Blartrate 20 MG Extended Release Oral Cantolia		🖉 🔝 Baltussin HC 🕅			- A	£											
III Human	12 HR I	HYDROcodone Bitartrate 30 MG Extended Release Oral Capsule		🔣 🛄 Baitussin HC (chi	crphe B3	- T   Z		Jx rx	cui										
(m) Vet	HUT 12 HR	HYDROcodone Bitartrate 40 MG Extended Release Oral Capsule		Bromplex HD (															
R Pres	H 10 5 12 HR I	HYDROcodone Bitartrate 50 MG Extended Release Oral Capsule		Brompley HD 2/1	7/30 A	B	C	D	E	F	G	н	I	J	ĸ	L	M	N	0
(m) Single	H II Abuse-	Deterrent 24 HR HYDROcodone Bitertrate 100 MG Extended Release Oral Tablet			1 5489 sim	ple													
Group      Form	HILE Abuse-	Deterrent 24 HR HYDROcodone Bitartrate 120 MG Extended Release Oral Tablet		Cytuss-HC NR	2														
	H Ca Abuse-	Deterrent 24 HR HYDROcodone Bitatrate 20 MG Extended Release Oral Tablet		Cytuss-HC NR (c	exord 2														
Links	ADUSE-	Deterrent 24 MM M //DMOcodone Bitartrate 30 MG Extended Release Oral Tablet		De-Chlor G (1)	3 termType	e rxcui	name	isHuman	DisVetDrug	g isPrescrib	bable								
o Drug Label	Aburn	Deterrent 24 MR HYDROnorinne Blantrate 40 MG Extended Release Oral Tablet		De-Chlor G (guai	FENel 4 BN	128793	Vicodin	US		Y									
- Meriline Plus	Abuse-	Deterrent 24 HR HYDROcodone Ritertrate 80 MG Extended Release Oral Tablet		De Chier HC III		05 60 07		1000 (1000			(	1.00.1.1.1							
@ Doug Bostal	HYDRO	Ocodone Bitartrate 7.5 MG Oral Tablet		De Chine MC (1)	5 SBD	856907	vicoain 5	/500 (HYD	ROcodone	bitartrate,	/ APAP) Or	ai iabiet							
a brog Portan	(D) IT builden	sincehen / Assisin / Catholes / INTRODUCED		Description in fem	6 SBD	1310212	Vicodin E	SUS		Y									
Legend	C Lincola	andpoint ( respect) ( carrience ) if Construction		De-Chlor MR (1)	7 SBD	1310202	Vicodin 5	US		Y									
A MIN C Pack Mutt	Acetan	sinophen / butalbital / Caffeine / HYDROcodone		De-Chipr MR (H)	DROI COD	1210270	Mine alian 1												
Dosminad	O DAcidae	sinonhen / Catterine / Chlomberdramine / HVDD/Cendone / Phendenhrine	5	De-Chlor NX (1)	0 560	1310270	VICOUIN H	1105		T									
	C Dresses	interprise ( carriers / careford manine ( ) ( consistent / Printpaperine	17	De-Chlor NX (put	sacob 9 BN	144254	Lortab	US		Y									
Collegue Al	V @HOM Acetan	ninophen / HYDROcodone (27)		Contract Hill Link	10 SBD	1495472	<b>APAP 325</b>	i us		Y									
	H Acetam	inophen 20 MG/ML / HYDROcodone Bitartrate 0.667 MG/ML Oral Solution		Diffuss HD (1)															
	Acetam	inophen 21.7 MG/ML / HYDROcodone Bitartrate 0.5 MG/ML Oral Solution		Chebis ND (goal	ENES II SBD	1495474	Lortab 5/	305		T									
	H RE Acetam	mophen 21.7 MG/ML / HYDROcodone Bitartrate 0.67 MG/ML Oral Solution		Drotuss CP (1)	12 SBD	1495476	APAP 325	5 US		Y									
	H Contain	Incomen 300 Mill / H rumocodone Desirate rumo oral ravet		Drotuse CP (chis	rphen 13 SBD	857105	Lortab 7.5	5/500 per 1	15 ML Syrun										
	Acetam	incohen 300 MS / HYDROcotione Blartrate 7.5 MS Oral Tabler		Dytan-HC (1)	14 600	057110	Lastala D.C.		DO		(4040) 0	al Tablet							
	HITH Acetam	inophen 325 MG / HYDROcodone Bitertrate 10 MG Oral Tablet		Dytan-HC (deher	whydri 14 SBD	857113	Lortab 2.5	5/500 (HTD	Rocodone	bitartrate	7 APAP) OI	rai rabiet							
	H IT M Acetam	inophen 325 MG / HYDROcodone Bitartrate 2.5 MG Oral Tablet			15 SBD	857117	Lortab 5/	500 (HYDR)	Ocodone b	itartrate / .	APAP) Oral	l Tablet							
	H III Acetam	inophen 325 MG / HYDROcodone Bitartrate 5 MG Oral Tablet		Entuss-D Liquid	16 SBD	857109	Lortab 10	/500 (HYDI	ROcodone I	bitartrate /	APAP) Or	al Tablet							
	HIII Acetam	inophen 325 MG / HYDROcodone Bitartrate 7.5 MG Oral Tablet		M Eutros-D Lidna (	17 600	057100	Louise 77	(500 Oml	Tablat	,	, ,								
	Acetam	inophen 33.3 MG/ML / HYDROcodone Bitertrate 0.333 MG/ML Oral Solution		Exetuss HC (1)	17 580	857120	Lortab 7.5	5/500 Orai	Tablet										
	Acetam	inophen 33.3 MG/ML / HYDROcodone Bitartrate 0.5 MG/ML Oral Solution		Exetuse HC (gua	FENr 18 SBD	1442445	APAP 20 I	NUS		Y									
	Acetam In Acetam	Incohen 33.3 MiGAML / HYDROcodone Distribute 10.467 Angrinit, Unit Solution		ELECTRI Flowbuss (1)	19 BN	151875	Hydrome	tus		Y									
	CITE Acetam	incohen 400 MG / HYDROcotone Btartrate 5 MG Oral Tablet		Fewture (HYDR)	Contino com	002675													
	Acetam	inophen 400 MG / HYDROcodone Bitartrate 7.5 MG Oral Tablet			20 580	992075	нуаготте	i US		T									
	Acetam	inophen 500 MG / HYDROcodone Bitartrate 10 MG Oral Tablet		Hy-KXP (1)	21 BN	216748	Drituss HI	D											
	Acetam	nirophen 500 MG / HYDROcodone Bitartrate 2.5 MG Oral Tablet		My-KXP (gualaco	22 SBD	860446	Drituss H	D (quaiFEN	lesin 100 M	AG / HYDRC	Codone bi	tartrate 2.5	MG / nseur	doenhedi	ine 30 MG	i) per 5 M	Elixir		
	🔛 Acetam	inophen 500 MG / HYDROcodone Bitartrate 5 MG Oral Capsule		Hy-Phen (1)	22 000	216027	Contract D	t laurial					, press			,			
	Acetam	inophen 500 MG / HYDROcodone Bitartrate 5 MG Oral Tablet		Hy-Phen 5/500 (P	TYDRI 23 BIN	210927	Entuss-D	Liquid											
	Acetam	Inophen 500 MG / HYDROcodone Bitartrate 7.5 MG Oral Tablet		ENCOME Harved (1)	24 SBD	1248039	Entuss-D	Liquid (HY	DROcodon	e bitartrat	e 5 MG / ps	eudoephe	drine HCl 60	DMG) per	5 ML Oral	Solution			
	III Acetam	Wophen 550 MG / HYDROcostere Blantate 50 MG Crai Tablet		ADIO 21 7 MO AL	25 BN	217574	Hv-Phen												
	Acetam	inophen 650 MG / HYDROcodone Bitartrate 7.5 MG Oral Tablet		Martin Perse & C. C. Martin	26 600	057070	the Disease	r (r.oo (i.p.)	and and an a			and Tables							
	Acetam	inophen 660 MG / HYDROcodone Bitartrate 10 MG Oral Tablet		HRM Hycofenix (1)	20 580	857370	Hy-Phen:	5/500 (HYL	DROcodone	e / acetami	nophen) O	rai rabiet							
	Acetam	inophen 750 MG / HYDROcodone Blartrate 10 MG Oral Tablet		HICK Hycofenix (HYDR	EDcod 27 BN	217668	Hyphed												
	Acetam	Wophen 750 MG / HYDROcodone Bitartrate 7.5 MG Oral Tablet		Hydro GP [1]	28 SBD	858937	Hyphed 2	/2.5/30 (d	hlorohenira	amine / HY	DROcodon	e / nseudo	enhedrine)	per 5 MI	Oral Solut	tion			
	O DAspirin	/ Caffeine / HYDROcodone		Hydro GP (gualFi	ENesi no Phi	240252		- 110				, preduce		paratio					
				The standard Diff in 172	29 BIN	218252	waxi-rus	SHC											
	💛 💮 🔣 🔛 Aspirin	I / HYDROcodone (1)		mydro-rec II (2)	30 SBD	858840	Maxi-Tus	s HC (chlor	rphenirami	ine 2 MG /	HYDROcod	one bitartr	ate 2.5 MG /	/ phenyle	phrine 5 M	/IG) per 5	ML Oral Sol	ution	
					31 BN	218580	Nalex Exr	pectorant											
					22 680	1248044	Nolov C.	o octorart i	(muniFER!	10 200 100	/HYDRC	dono hit-r	trata E MC	l neoud	nhodri	hudrocht	orido 60 ***	1 0015	AL Oral Solution
					32 580	1248044	indiex Exp	pectorant (	Regainerves	200 MG	7 HTURUCO	oone bitar	u ate 5 MG /	pseudoe	phearine	nyarochi	onde ou Mo	i) per 5 №	IL Oral Solutio
					33 BN	218772	Norco	US		Y									
					34 SBD	857001	Norco 10/	/ US		Y									
					25 SBD	857004	Norco E/S	2115		v									
					33 360	007004	140100 3/3												

36 SBD

857007 Norco 7.5/ US

### Step II: Pattern SEARCH on GENERIC Names of opioid drugs

- Missing RxNormCUI information
- Pattern search on generic opioid medications
  - Hydrocodone
  - Oxycodone
  - Tramadol
  - Codeine
  - Morphine
  - Methadone
  - Fentanyl
  - Hydromorphone
  - Oxymorphone
  - Meperidine
  - Tapentadol
- Use RxMix to identify the RxCUIs

#### + Step II: Pattern SEARCH on GENERIC Names of opioid drugs

4	RxMix	
Create application: from RxNorm.	RxTerms, NDF-RT, and RxImageAccess APIs	
WORKFLOW Build		
RxNorm findFxcuiByString No function selected + @	• Documentation	
Do a normalized string search Remove Last Save From my workflow library Email *: et@ochin.org My 75a R.Norm Name Click to load an Input File File: missing rx norm.tst CUTPUT CU	<ul> <li>KrNora</li> <li>JindRiculty/Property</li> <li>JindRiculty/String</li> <li>Search by name to find ReNorm concepts</li> <li>INPUT: search string: source type: allSourcestFlag: searchType</li> <li>OUTPUT: EXCEN</li> <li>Do an exact match search</li> <li>Do a normalized string search</li> <li>For more information click here.</li> <li>getall/Cloases</li> <li>g</li></ul>	
EXECUTE	• Output	
Clear Submit Batch	First time user? Check our <u>RsMix tutorial</u> .	

https://mor.nlm.nih.gov/RxMix/





### Percentage of adults with >= 1 opioid prescription by year



+

### Percentage of adults with >=1 opioid prescription by age group



4. Percentage of adults with >=1 opioid prescription in 2016 by sex and age group

5. Percentage of adults with >=1 opioid prescription in 2016 by payor type



### 6. Percentage of adults with >=1 opioid prescription in 2016 by Race

7. Percentage of adults with >=1 opioid prescription by sex and ethnicity





+

### 8. Percentage of all adults with $\geq 10$ opioid prescription by year.



Most prescribed opioid medication by generic name

Generic Name	Orders
Hydrocodone	160,766
Oxycodone	106,238
Tramadol	61,523
Codeine	35,743
Morphine	23,770
Methadone	12,287
Fentanyl	8,797
Hydromorphone	3,471
Oxymorphone	380
Meperidine	254
Tapentadol	222

# Defining chronic opioid use using population data Annual number of prescriptions vs. a predefined MME

- EHR Order Data
  - Unique Med Order ID
  - Unique Patient ID
  - Date of prescription order
  - Name of medication
  - Unit of medication (MG, MG/ML, MCG/HR)
  - Strength of ordered medication per unit
  - Number of units ordered
  - Frequency at which it should be taken
  - Example: Order20010111, MRN1002010, 1/25/2015, Oxycontin, Mg, 10, 90, Take one three times daily.
- And extrapolate:
  - Number of morphine milliequivalents per prescription (from name, strength, unit, number of units
  - Long acting vs. short acting medicine (from name)
  - Initiation date

# + One Urban FQHC in Portland

- 8080 adults with at least one ambulatory visit in 2015
- Followed forward for one year after index visit and opioid prescriptions assessed.
- 1757 with at least one prescription for an opioid (22%)
- 15160 distinct opioid prescription orders (avg 8.6)
  - 81% did not have a discrete "sig", so expected frequency wasn't clear.
- The clinic keeps a list of "chronic opioid users" = 540 patients (in 2015)

# Count of opioid prescriptions for each patient

600

Number of opioid prescriptions per patient



### FQHC 2015 8080 adults, 1757 with at least 1 opioid prescription



<b>Opioid number</b>	Number of patients	Percentage
1	477	27%
>8	683	39%
>10	613	35% (7.6% of clinic adults)

Opioid type	Number of patients	Percentage
Long acting	46	3%
Short acting	227	13%
Both LA and SA	1479	84%

#### Milligram Morphine Equivalents (MMEs)

Major Group	Type of Opioid	Morphine equivalent conversion factor per mg of opioid
Short-acting Non-Schedule II	Propoxyphene (with or without aspirin/acetaminophen/ibuprofen)	0.23
	Codeine + (acetaminophen, ibuprofen or aspirin)	0.15
	Hydrocodone + (acetaminophen, ibuprofen, or aspirin) Hydrocodone and homatropine	1.0
	Tramadol with or without aspirin	0.10
	Butalbital and codeine (with or without aspirin, ibuprofen, acetaminophen)	0.15
	Dihydrocodeine (with or without aspirin, ibuprofen, acetaminophen)	0.25
	Pentazocine (with or without aspirin, ibuprofen, acetaminophen)	0.37
Short-acting, Schedule II	Morphine sulfate	1.0
	Codeine sulfate	0.15
	Oxycodone (with or without aspirin, acetaminophen, ibuprofen)	1.5
	Hydromorphone	4.0
	Meperidine hydrochloride	0.1
	Fentanyl citrate transmucosal <sup>2</sup>	0.125
	Oxymorphone	3.0
Long-acting (Schedule II)	Morphine sulfate sustained release	1.0
	Fentanyl transdermal <sup>3</sup>	2.4
	Levorphanol tartrate	11.0
	Oxycodone HCL controlled release	1.5
	Methadone	3.0

Sullivan, M. D., M. J. Edlund, M. Y. Fan, A. Devries, J. Brennan Braden, and B. C. Martin. "Trends in Use of Opioids for Non-Cancer Pain Conditions 2000-2005 in Commercial and Medicaid Insurance Plans: The Troup Study." *Pain* 138, no. 2 (Aug 31 2008): 440-9.

# Milligram morphine equivalents prescribed for the year

Total MME	Total/365	No. Patients (% of 1757)
<1825	<5	949 (54)
1826-5474	5-14.9	262 (14.9)
5475-18249	15-49.9	296 (16.8)
18250-32849	50-89.9	97 (5.5)
>32850	>=90	153 (8.7)

# + Opportunities

- Medication orders are mostly defined vocabulary from that clinicians select from lists, and therefore reliably accurate.
- There is a great deal of unexplored data in the clinical records concerning visits and patient characteristics that have yet to be explored and tracked.
- Thus far, studies have been retrospective analyses. Do they need to be?
  - Once opioid prescriptions are appropriately identified, there is opportunity for regular surveillance on a nearly real time basis.





- The larger the study population, the more generalizable. Combining data from different EHRs is complicated.
- The data is only as good as the entry. Example: clinicians free-text the patient instructions, or "sig", it becomes difficult to calculate a daily MME.
- Electronic health records count prescription orders, not fills.
   But perhaps we can assume excellent medication adherence when it comes to opioids.





- Continue organizing and exploring ADVANCE data as infrastructure for further studies
- New CDC Prescribing Guidelines can we tease out the effect?
- Benzodiazepines
- Funding

## Future directions

- Linking to other data sets
  - Social determinants of health data
  - Prescription drug monitoring program data
  - State vital statistic registries
- Patient reported data (adverse childhood experiences)
- Identifying overdoses in EHRs?
  - Green, C. A., N. A. Perrin, S. L. Janoff, C. I. Campbell, H. D. Chilcoat, and P. M. Coplan. "Assessing the Accuracy of Opioid Overdose and Poisoning Codes in Diagnostic Information from Electronic Health Records, Claims Data, and Death Records." *Pharmacoepidemiol Drug Saf* (Jan 10 2017).
- Pain!
  - Von Korff, M., A. I. Scher, C. Helmick, O. Carter-Pokras, D. W. Dodick, J. Goulet, R. Hamill-Ruth, et al. "United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data." J Pain 17, no. 10 (Oct 2016): 1068-80.



#### **Questions, Answers, and Discussion**



**Contact Information:** 

John Muench, MD: muenchj@ohsu.edu

Thuy Le, MPH: let@ochin.org

Jon Puro, MHA: puroj@ochin.org